ADC Therapeutics, founded in 2011?with financial backing of US $50 million by Auven Therapeutics,?is developing a pipeline of proprietary Antibody Drug Conjugates (ADCs) for the treatment of both solid and hematological cancers.
Monoclonal antibodies specific to particular types of tumor cells are combined with a novel class of highly potent pyrrolobenzodiazepine (PDB)-based warheads (developed by ADC Therapeutics’ partner?Spirogen Limited)?to selectively kill cancer cells.?Selective targeting should mean fewer side effects for patients and avoids repair-related resistance in continued treatment faced by other anti-cancer products on the market.

Rue Saint-Pierre 2,
Lausanne, 1003,

Web:?ADC Therapeutics S.a.r.l

Advertisement #5